LB PharmaceuticalsvsEli Lilly and Company

LBRX and LLY stock compared: price, dividend, valuation and results, from SEC filings.

LBRX

LB Pharmaceuticals Inc

$40.06

Value $1.3B

-0.60%
LBRX's page

LLY

Eli Lilly and Company

$1,382.75

Value $1.30T

-2.32%
LLY's page

LB Pharmaceuticals (LBRX) has a market value of $1.3B and Eli Lilly and Company (LLY) $1.30T. Over the last year, with dividends, LBRX moved +135.0% and LLY +36.2%. Dividend yield: LBRX none, LLY 0.46%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LBRX$1.3B

    LLY$1.30T

    LLY is 1,006 times LBRX

  • Revenue, 12 months

    LBRX–

    LLY$86.5B

  • Net income, 12 months

    LBRX-$141M

    LLY$27.6B

  • Operating margin

    LBRX–

    LLY–

  • ROIC

    LBRX-6.6%

    LLY35.5%

    42.1 points apart

  • P/E

    LBRX–

    LLY47.3

  • Dividend yield

    LBRX0.0%

    LLY0.5%

    0.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LBRX+135.0%

LLY+36.2%

100200300DecFebAprJunAugOct
Returns by period
PeriodLBRXWith dividendsLLYWith dividends
1 year since November 17, 2025+135.0%Price +135.0%+36.2%Price +35.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LBRXLB PharmaceuticalsLLYEli Lilly and Company

Valuation

LBRXLLY
Valuation
Price$40.06$1,382.75
Market value$1.3B$1.30T
Enterprise value (EV)$893M$1.35T
P/E–47.3
P/E, 5-year median–49.9
P/B3.132.4
EV/EBIT–38.8
Free cash flow yield–1.5%

Results and growth

LBRXLLY
Results and growth
Revenue, 12 months–$86.5B
Net income, 12 months-$141M$27.6B
Free cash flow, 12 months-$144M$19.7B
Earnings per share, 12 months-$1.04$30.81
Revenue growth, year on year–44.7%
Revenue growth a year, past–+21.6%over 5 years
EPS growth a year, past–+27.6%over 5 years

Margins and returns on capital

LBRXLLY
Margins and returns on capital
Gross margin–83.6%
Operating margin––
Net margin–31.9%
ROIC-6.6%35.5%
ROE-40.6%88.6%

Balance sheet

LBRXLLY
Balance sheet
Cash$403M$4.9B
Total debt$5.2M$49.5B
Net debt / EBITDA–1.2
Interest cover–38.9×

Dividends and buybacks

LBRXLLY
Dividends and buybacks
Dividend yield–0.5%
Dividend per share, 12 months–$6.34
Dividend growth a year, past–+15.2%over 5 years
Buyback yield–0.3%
Shareholder yield–0.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LBRX or LLY

Didn't find what you were looking for?

Ask us
Which is bigger, LB Pharmaceuticals or Eli Lilly and Company?

By market value, Eli Lilly and Company ($1.30T) is about 1,006.1 times LB Pharmaceuticals ($1.3B), at today's prices.

How did LBRX and LLY stock do over the last 1 years?

Since November 17, 2025, LBRX's price moved +135.0% and LLY's +35.3%. With dividends: LBRX +135.0% (+135.0% a year), LLY +36.2% (+36.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, LBRX or LLY?

The dividend yield at today's price is none for LB Pharmaceuticals and 0.46% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.

Which is the better investment, LB Pharmaceuticals or Eli Lilly and Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.